Literature DB >> 26769184

Heavy Testosterone Use Among Bodybuilders: An Uncommon Cohort of Illicit Substance Users.

Mary E Westerman1, Cameron M Charchenko1, Matthew J Ziegelmann1, George C Bailey1, Todd B Nippoldt2, Landon Trost3.   

Abstract

OBJECTIVE: To identify and characterize patterns of use among a contemporary cohort of current anabolic-androgenic steroid (AAS) users. PATIENTS AND METHODS: An anonymous, self-administered, 49-item questionnaire was posted on message boards of Internet websites popular among AAS users and administered via SurveyMonkey from February 1, 2015, to June 1, 2015. Thirty-seven questions were analyzed for this study.
RESULTS: A total of 231 male respondents met the inclusion criteria. Most were white, were older than 25 years, were employed with above average income, and had received a formal education beyond high school. Ninety-three percent began using AAS after the age of 18 years, and 81% reported using 400 mg or more of testosterone per week. Factors associated with longer duration of use (>5 years) included higher incomes (≥$75,000, P=.003), increased testosterone dosages (>600 mg per week, P=.007), older age (≥35 years, P<.001), being married (P<.001), and being self-employed (P<.001). The Internet was the most common source of testosterone (53%). Ninety-three percent used at least one additional performance-enhancing drug. Seventy-seven percent had routine laboratory tests performed, and 38% reported laboratory abnormalities at some point. Nearly all experienced subjective adverse effects while using and not using testosterone. Fifty-three percent reported use of other illegal substances, most commonly (90%) beginning before AAS initiation. Ten percent had a criminal conviction, 91% of which preceded AAS use. Fifty percent were felonies.
CONCLUSION: The population of AAS users is disparate from that of other drugs of abuse. Laboratory test abnormalities and adverse effects are common and should be taken into account when counseling patients who may be using AASs.
Copyright © 2016 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26769184     DOI: 10.1016/j.mayocp.2015.10.027

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  8 in total

Review 1.  Supraphysiologic-dose anabolic-androgenic steroid use: A risk factor for dementia?

Authors:  Marc J Kaufman; Gen Kanayama; James I Hudson; Harrison G Pope
Journal:  Neurosci Biobehav Rev       Date:  2019-02-25       Impact factor: 8.989

2.  Chemical Composition and Labeling of Substances Marketed as Selective Androgen Receptor Modulators and Sold via the Internet.

Authors:  Ryan M Van Wagoner; Amy Eichner; Shalender Bhasin; Patricia A Deuster; Daniel Eichner
Journal:  JAMA       Date:  2017-11-28       Impact factor: 56.272

3.  Prevalence of anabolic steroid users seeking support from physicians: a systematic review and meta-analysis.

Authors:  Julio Mario Xerfan Amaral; Andreas Kimergård; Paolo Deluca
Journal:  BMJ Open       Date:  2022-07-04       Impact factor: 3.006

4.  Acute Pectoralis Major Rupture Captured on Video.

Authors:  Alejandro Ordas Bayon; Enrique Sandoval; María Valencia Mora
Journal:  Case Rep Orthop       Date:  2016-08-10

Review 5.  Testosterone replacement in the infertile man.

Authors:  Ahmad Majzoub; Edmund Sabanegh
Journal:  Transl Androl Urol       Date:  2016-12

6.  Defining the Construct of Synthetic Androgen Intoxication: An Application of General Brain Arousal.

Authors:  Tom Hildebrandt; Ashley Heywood; Daniel Wesley; Kurt Schulz
Journal:  Front Psychol       Date:  2018-03-29

7.  The Impact of the COVID-19 Pandemic on Male Strength Athletes Who Use Non-prescribed Anabolic-Androgenic Steroids.

Authors:  Barnaby N Zoob Carter; Ian D Boardley; Katinka van de Ven
Journal:  Front Psychiatry       Date:  2021-03-22       Impact factor: 4.157

8.  Impact of anabolic androgenic steroids on sexual function.

Authors:  Joseph Matthew Armstrong; Ross A Avant; Cameron M Charchenko; Mary E Westerman; Matthew J Ziegelmann; Tanner S Miest; Landon W Trost
Journal:  Transl Androl Urol       Date:  2018-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.